Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: A mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia

OTHER RELATED OMICS DATASETS IN: E-GEOD-20987

PROVIDER: PRJNA232633 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR1061454.fastq.gz	Fastqsanger.gz
	SRR1061455.fastq.gz	Fastqsanger.gz
	SRR1061456.fastq.gz	Fastqsanger.gz
	SRR1061457.fastq.gz	Fastqsanger.gz
	SRR1061458.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

Mus musculus

Project description:A mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia [array]

| PRJNA232634 | ENA

Mus musculus

Project description:A mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia [HTS]

| PRJNA232635 | ENA

E-GEOD-45834

Project description:Germline Aberrations of PAX5 Cause Susceptibility to pre-B cell Acute Lymphoblastic Leukemia

2015-07-13 | E-GEOD-45834 | ExpressionAtlas

E-MTAB-9250

Project description:Glucocorticoids induced transcriptional regulation in acute lymphoblastic leukemia

2025-01-16 | E-MTAB-9250 | ExpressionAtlas

E-GEOD-26790

Project description:Gene expression profile of acute lymphoblastic leukemia cell lines treated with panobinostat

2025-01-24 | E-GEOD-26790 | ExpressionAtlas

E-MTAB-3322

Project description:Targeting epigenetic networks mediated by Prmt1 and Kdm4c in acute myeloid leukemia

2019-05-14 | E-MTAB-3322 | ExpressionAtlas

Dual targeting of BCR-ABL1 and IRE1α is a promising therapeutic strategy in Ph+ ALL

Project description:BCR-ABL positive acute lymphoblastic leukemia (ALL) cell survival is strongly dependent on the IRE1α-XBP1 branch of the Unfolded Protein Response (UPR). In the study at hand, we have focused on exploring the link between BCR-ABL1 and IRE1α to better understand whether a simultaneous pharmacological inhibition of both pathways could represent a beneficial therapeutic strategy in Philadelphia positive (Ph+) ALL. Therefore, the effect on the phosphoproteome of two inhibitors (MKC-8866 and Nilotinib) as well as a combination of both compounds was analysed in this study.

2020-09-21 | PXD012024 | Pride

Targeting Senescent Stem-Like Subpopulations in Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

Project description:Philadelphia chromosome-like B-cell acute lymphoblastic leukemia (Ph-like ALL) is driven by genetic alterations that induce constitutive kinase signaling and is associated with chemoresistance and high relapse risk in children and adults. Preclinical studies in the most common CRLF2-rearranged/JAK pathway-activated Ph-like ALL subtype suggest incomplete oncogene addiction and partial response to tyrosine kinase inhibitor (TKI)-based therapies, highlighting a need to elucidate alternative biologic dependencies and therapeutic vulnerabilities, although the ABL-class Ph-like ALL subtype may be preferentially TKI-sensitive. Using bulk and single-cell multiomics analyses, we profiled residual cells from Ph-like ALL xenograft models treated in vivo with inhibitors to identify mechanisms of potential therapeutic escape. We identified a specific MYC dependency in Ph-like ALL and defined a leukemia cell subpopulation with senescence-associated stem cell-like features regulated by AP-1 transcription factors. This dormant ALL subpopulation could be eradicated by dual pharmacologic inhibition of JAK/STAT and BCL-2, providing mechanistic rationale for alternative therapeutic approaches.

2025-01-28 | PXD053611 | Pride

E-GEOD-5681

Project description:Transcription profiling of human T-cell lymphoblastic leukemia, acute mylelogenous leukemia and Diffuse Large Cell Lymphoma cell lines after treatment with aplidin and/or cytarabine

2025-01-24 | E-GEOD-5681 | ExpressionAtlas

SETDB2 links E2A-PBX1 to cell cycle dysregulation in acute leukemia through CDKN2C repression [sequencing]

Project description:Acute lymphoblastic leukemia (ALL) is associated with significant morbidity and mortality necessitating further improvements in diagnosis and therapy. Targeted therapies directed against epigenetic regulators, which are frequently mutated or misregulated in acute leukemia, are emerging as candidate approaches in preclinical studies and early trials. However, the epigenetic factors involved in most ALLs are not well defined or functionally characterized. In this study, we demonstrate an oncogenic role for the protein lysine methyltransferase SETDB2 in leukemia pathogenesis. It is over-expressed in a wide spectrum of leukemias, required for their maintenance in vitro and in vivo, and its elevated expression correlates with a poor prognosis in clinical cohorts. In a subset of ALL with the preBCR+ phenotype, SETDB2 expression is maintained as a direct target gene of the chimeric transcription factor E2A-PBX1. In this subset, SETDB2 epigenetically suppresses expression of the cell cycle inhibitor CDKN2C through histone H3K9 tri-methylation thus establishing a novel oncogenic pathway subordinate to E2A-PBX1 that silences a major tumor suppressor in ALL. In contrast, SETDB2 was relatively dispensable for normal hematopoietic stem and progenitor cell proliferation. In addition to targeting SETDB2 alone, its knockdown significantly enhanced sensitivity to kinase and epigenetic inhibitors suggesting a potential approach to future combination treatments. Our studies define an epigenetic role for SETDB2 in leukemia pathogenesis, and provide a mechanistic rationale for targeting SETDB2 therapeutically in a subset of leukemia.

2018-05-30 | GSE102947 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data